Polymer‐delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open‐label studies in patients with advanced prostate cancer

D. Shore, Neal; Chu, Franklin; W. Moul, Judd; R. Saltzstein, Daniel; S. Concepcion, Raoul; A. McLane, John; Atkinson, Stuart; Yang, Alex; David Crawford, E.

doi:10.1111/bju.13482

Public

Polymer‐delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open‐label studies in patients with advanced prostate cancer

Published in British Journal of Urology • Mar 19, 2016

Authors:

Neal D. Shore

Franklin Chu

Judd W. Moul

Abstract

OBJECTIVE: polymer-delivered, subcutaneous, leuprolide acetate (ADSC-LA), formulations suppressed serum testosterone to concentrations of ≤20 ng/dL. PATIENTS AND METHODS: Data from four open-label, fixed-dose studies were evaluated. Male patients aged 40-86 years with advanced prostatic adenocarcino...

Subject

Medicine

Testosterone (patch)

Leuprorelin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!